Bespoke CRISPR Gene Therapy: Why Baby KJ’s Six-Month Cure Is a Gulf Game-Changer

In February 2025, Penn Medicine reported that an infant, KJ Muldoon, became the world's first patient to receive a made-to-order CRISPR gene therapy, specifically base editing, for a rare, lethal urea cycle disorder (Penn Medicine).

Nature Biotechnology confirmed in August 2025 the launch of a $20 million 'Children with Rare Genetic Diseases CRISPR Center' in San Francisco, aiming to replicate and scale such rapid, patient-specific therapies (Nature Biotechnology).

Axios, in February 2026, detailed how the FDA introduced a streamlined regulatory route for one-off gene therapies after KJ's success, aiming to speed access for similarly affected patients (Axios).

Treatments for rare genetic diseases typically take years to develop, while patients with rapidly progressing symptoms often die waiting. KJ’s case shattered that timeline: a therapy began development at birth and was ready within six months, then administered with no serious side effects, according to Penn Medicine.

This is not an off-the-shelf drug but a process that identifies the patient’s unique mutation and engineers a bespoke CRISPR fix, tested and approved under a new regulatory playbook inspired by KJ's outcome.

The scale-up is still early. Repeatability and cost remain big questions; most rare diseases lack even this level of research attention, and long-term results are unproven. For now, these therapies are available only at a handful of centers in North America, but the scientific and regulatory precedent has shifted.

FDA’s pathway is expected to cut approval timelines for individual therapies, but patient safety and ethical scrutiny are still front and center. Policymakers will need to balance rapid access with thorough proof of benefit and risk.